Idiopathic Sudden Sensorineural Hearing Loss
Article Sidebar
Main Article Content
Abstract
Sudden sensorineural hearing loss (SSNHL) is characterized by a rapid or abrupt decrease in hearing ability, typically occurring within a 72-hour period. Its annual prevalence is estimated to range from 5 to 27 cases per 100,000 individuals.1 More than 90% of this illness is idiopathic, which implies fewer than 10% attributed to identifiable factors. This condition is urgent since early diagnosis allows for earlier treatment initiation, leading to improved outcomes and enhanced quality of life for patients. Numerous studies have been conducted in the past and have continued to advance up to this day. The authors are aware of the necessity of evidence-based practice and attempt to synthesize available data from reliable databases that could provide both physicians and patients with useful information on treatment choices.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the Royal Thai Army Medical Department and published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.
Use or modification of the articles is prohibited without permission.
Statements expressed in the articles are solely the opinions of the authors.
Authors are fully responsible for the content and accuracy of their articles.
Any other republication of the articles requires permission from the journal.
References
Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019;161(1_suppl):S1-S45.
Schreiber BE, Agrup C, Haskard DO, Luxon LM. Sudden sensorineural hearing loss. Lancet. 2010;375(9721):1203-11.
Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1977;86(4 Pt 1):463-80.
Li H, Feng G, Wang H, Feng Y. Intratympanic Steroid Therapy as a Salvage Treatment for Sudden Sensorineural Hearing Loss After Failure of Conventional Therapy: A Meta-analysis of Randomized, Controlled Trials. Clin Ther. 2015;37(1):178-87.
Wei BP, Stathopoulos D, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2013;2013(7):CD003998.
Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol. 1980;106(12):772-6.
Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. Eur Arch Otorhinolaryngol. 2001;258(9):477-80.
Nosrati-Zarenoe R, Hultcrantz E. Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial. Otol Neurotol. 2012;33(4):523-31.
Crane RA, Camilon M, Nguyen S, Meyer TA. Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope. 2015;125(1):209-217.
Eftekharian A, Amizadeh M. Pulse steroid therapy in idiopathic sudden sensorineural hearing loss: A randomized controlled clinical trial. Laryngoscope. 2016;126(1):150-5.
Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7 Pt 2):1-17.
Filipo R, Attanasio G, Russo FY, Viccaro M, Mancini P, Covelli E. Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope. 2013;123(3):774-8
Garavello W, Galluzzi F, Gaini RM, Zanetti D. Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otol Neurotol. 2012; 33(5):724-9.
Plontke SK, Meisner C, Agrawal S, Cayé-Thomasen P, Galbraith K, Mikulec AA, et al. Intratympanic corticosteroids for sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2022;7(7):CD008080.
Yang J, Huang L, Shi J, Li Y, Wu H, Kong W. [The effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Zhi. 2021;24:594-7. Chinese.
Tarkan O, Dagkiran M, Surmelioglu O, Ozdemir S, Tuncer U, Dogrusoz M, et al. Intratympanic Methylprednisolone versus Dexamethasone for the Primary Treatment of Idiopathic Sudden Sensorineural Hearing Loss. J Int Adv Otol. 2018;14(3):451451-5.
Berjis N, Soheilipour S, Musavi A, Hashemi SM. Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv Biomed Res. 2016;5:111.
Nelson L, Swanson D, Borowiec E, Crossley J, Geng X, Cao X, et al. The Impact of Intratympanic Steroid Dosage on Hearing Recovery in Sudden Sensorineural Hearing Loss. Ann Otol Rhinol Laryngol. 2023;132(8):879-87.
Salvador P, Moreira da Silva F, Fonseca R. Idiopathic sudden sensorineural hearing loss: Effectiveness of salvage treatment with low-dose intratympanic dexamethasone. J Otol. 2021;16(1):6-11.
Kanotra S, Kumar A, Langar B, Kalsotra P, Paul J. Intratympanic Dexamethasone in Sudden Sensorineural Hearing Loss. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 3):3947-56.
Li J, Ding L. Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials. Ann Pharmacother. 2020;54(10):949-57.
Han X, Yin X, Du X, Sun C. Combined Intratympanic and Systemic Use of Steroids as a First-Line Treatment for Sudden Sensorineural Hearing Loss: A Meta-Analysis of Randomized, Controlled Trials. Otol Neurotol. 2017;38(4):487-95.
Bae SC, Noh HI, Jun BC, Jeon EJ, Seo JH, Park SY, et al. Efficacy of intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss: comparison with systemic steroid therapy and combined therapy. Acta Otolaryngol. 2013;133(5):428-33.
Awad Z, Huins C, Pothier DD. Antivirals for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2012;2012(8):CD006987
Agarwal L, Pothier DD. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2009;2009(4):CD003422.
Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004;97(7):385-95.
Piper SM, LeGros TL, Murphy-Lavoie H. Idiopathic sudden sensorineural hearing loss [Internet]. 2011. [Cited 2024 Dec 12]. Available form: https://www.uhms.org/14-idiopathicsudden-sensorineural-hearing-loss-new-approved-on-october-8-2011-by-the-uhms-boardof-directors.html.
Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. 2017;47(1):24-32.
Tyagi BPS, Rout M. Platelet Rich Plasma (PRP): A Revolutionary Treatment of Sensorineural Hearing Loss. Acta Sci Otolaryngol (ASOL). 2019;1(4): 4p.
Sharma S, Patel VB, Chhatbar YB, Bhimani RJ, Rangani AM. Intratympanic Platelet-Rich Plasma Therapy for Sudden Sensorineural Hearing Loss: A Preliminary Prospective Study. Indian J Otolaryngol Head Neck Surg. 2024;76(6):5334-9.
Sherif AMH, Alawady MK, Mahfouz RM, Abbas AI, Ali HF. Comparative study between Intratympanic Steroid Injection and Intratympanic Platelet Rich Plasma (PRP) Injection in Sudden Sensorineural Hearing Loss (SSNHL). Al-Azhar Intern Med J. 2024;5(4):6p.
Shawky M. Management of Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) Intratympanic Platelet-Rich Plasma (PRP) Versus Intratympanic Steroid Injections: A CrossSectional Study. Otolaryngol Pol. 2024;78(3):1-6.
